Source comparison
Melanotan-2 for Erectile Dysfunction Research: Treatment Comparison
Melanotan-2 (MT-2). Melanocortin receptor agonist (MC4R activation in CNS) 2–4 hours 6–12 hours Not FDA-approved; investigational use only; side effects include nausea, flushing, and hyperpigmentation Used in studies modeling CNS-mediated erectile pathways, ps
This comparison does not assign a generated winner or score.
- Melanotan-2 (MT-2). Melanocortin receptor agonist (MC4R activation in CNS)
- 2–4 hours
- 6–12 hours
- Not FDA-approved; investigational use only; side effects include nausea, flushing, and hyperpigmentation
- Used in studies modeling CNS-mediated erectile pathways, psychogenic ED, and scenarios where peripheral PDE5 inhibition is insufficient
- Sildenafil (Viagra). PDE5 inhibitor (peripheral nitric oxide–cGMP pathway)
- 30–60 minutes
- 4–6 hours
- Requires intact nitric oxide signaling; ineffective in severe nerve damage or vascular insufficiency
- Gold-standard comparison for ED trials; works only when sexual stimulation triggers NO release
- Tadalafil (Cialis). PDE5 inhibitor with longer half-life
- 24–36 hours
- Same pathway as sildenafil; does not address CNS-mediated dysfunction
- Preferred for daily-dose protocols; allows spontaneous activity without timing constraints
- Apomorphine. Dopamine receptor agonist (D1/D2 receptors in hypothalamus)
- 20–30 minutes (sublingual)
- 2–3 hours
- High incidence of nausea and vomiting (30–40%); withdrawn from most markets
- Investigated as CNS-acting alternative but side-effect profile limited adoption